ABSTRACT
Because the assurance of analytical quality is critical for the reliable reporting of CBC analyses in laboratories that operate multiple automatic hematology analyzers, establishing interinstrument comparison methods for automatic hematology analyzers needs to be required to maintain quality control (QC), especially in laboratories that use multiple instruments. [1] [2] [3] These approaches include instrument calibration every 6 months, the daily measurement of QC materials, and inspecting results within the predefined acceptable range based on mean, SD, coefficient of variation (CV), and the interinstrument comparison with the 6-month interval using patient samples (>40 samples). [4] [5] [6] When a laboratory uses multiple instruments to measure a single item, the real-time evaluation of consistency between the reported results from each instrument is needed, especially if inpatient samples are analyzed using different instruments depending on the time of arrival of the sample. If the laboratory follows current guidelines 4-6 and performs interinstrument comparisons every 6 months, a relatively long inspection interval may not guarantee the real-time consistency of results from multiple instruments. Therefore, the daily inspection of precision using results from multiple instruments is necessary. In addition, the simultaneous collection of a sufficient number of patient samples (>40 samples) every 6 months that are suitable for the selection criteria 5 would be an extraordinary amount of work for the laboratory workers responsible for interinstrument comparisons.
If the laboratory operates the same models of instruments and uses the same QC materials, recently published guidelines suggest that the results of QC materials would be suitable for interinstrument comparisons as well as assessing patient samples. 7 However, the decision criteria for acceptable DOI: 10.1309/AJCPP0F9QXYOUJOG
© American Society for Clinical Pathology consistency that can be applied to QC results from multiple instruments have not been established. Therefore, the development of an interinstrument comparison method that can be performed daily and applied to both patient samples and QC materials is an important issue because it can reduce the unnecessary periodic workload of collecting many patient samples and guarantee daily-confirmed reliable reporting.
Here, we collected patient samples according to currently used selection criteria and performed CBC analysis of 11 items, using seven Sysmex XE-2100 automatic hematology analyzers (Sysmex, Kobe, Japan). Assessments were performed using patient samples for 6 months and three levels of QC materials for 4 months. Using these results, we developed an interinstrument comparison method based on the 99th percentile CV cutoff values of the daily means for each item and validated the practical relevance of this method. The main evaluation point in our present study was the development and validation of a real-time interinstrument comparison method applicable to multiple laboratory operating instruments using 99th percentile CV cutoff values.
Materials and Methods

Analysis and Patient Sample Selection
This study was approved by the Institutional Review Board in accord with the ethical standards established by the authors' institution.
A schematic flowchart summarizing the analysis strategy used in this study is presented in ❚Figure 1❚. A total of 120 patient samples, which were obtained following clinician request for CBC analysis, were analyzed over a 6-month period (July through December 2013) using current guidelines for the selection of patient samples used in interinstrument comparisons. 5 During the analysis period, a single sample was selected daily and CBC analysis was performed simultaneously using seven XE-2100 automated hematology analyzers. A total of 11 items were measured: WBCs, hemoglobin, platelets, five differential counts (segmented neutrophils, lymphocytes, monocytes, eosinophils, and basophils), reticulocytes (%), hematocrit, and mean corpuscular volume (MCV). Because the selection criteria for basophils (%), hematocrit, and MCV were not provided in the guidelines, basophils (%) were measured in the eosinophil samples, and both hematocrit and MCV were measured in the hemoglobin samples. A detailed acquisition strategy applied in this study and subsequent selection results are represented in ❚Table 1❚, ❚Table 2❚, and ❚Figure 2❚. 5 In brief, patient samples were obtained daily following the acquisition schedule described in Tables 1 and 2 (eg, samples with WBCs from 11.1 × 10 3 /µL to 25.0 × 10 3 / µL from the reference instrument XE-2108 on day 1, week 1, month 1) for 6 months, and the CBC results from seven instruments were recorded separately. CBC results of eight items obtained from reference instrument XE-2108 were classified into five groups as documented in the recently published Clinical and Laboratory Standards Institute (CLSI) © American Society for Clinical Pathology guideline. 5 At the end of sample acquisition for the first 3 months (months 1-3) and all 6 months (months 1-6), the total number of results in each group was calculated separately for each CBC item, as shown in Figure 2 . The adequacy of result distributions was evaluated according to the distribution criteria of the CLSI guideline. 5 Results considered outliers were excluded according to the previously suggested D/R ratio, 8, 9 where D indicates absolute difference between an extreme result (large or small) and the next largest or smallest results and R represents the range of all results obtained. The D/R ratio was calculated on all results of each CBC item, and if the D/R ratio exceeded 1:3, that result was considered an outlier and deleted. Identical examination was performed until the D/R ratios were within 1:3. Patient samples were divided into two 3-month periods. Data obtained during the first 3 months were used to determine the 95th and 99th percentiles of the CV cutoff values and SD values of the daily means for each item. Data obtained during the last 3 months were used to apply the 95th and 99th percentiles of the CV cutoff values, determine the acceptable range of daily means for each item, and calculate the rejection rates when the defined acceptable range of daily means was applied to validate this new method.
Determination of the 95th and 99th CV Cutoff Values Using the Results of the Patient Samples
An example of WBC data analysis is provided in ❚Figure 3❚, and the results of all items were analyzed using an identical method. Patient samples were obtained over 60 working days (single sample per working day) and analyzed with seven automated hematology analyzers. The daily mean, SD, and CV values of each sample measured from seven instruments were calculated. Using these results, the 95th and 99th percentiles of the CV values were calculated and used as cutoff values.
Validation of the 95th and 99th percentile CV Cutoff Values to Determine Daily Mean Values
An example of WBC data analysis is provided in ❚Figure 4❚, and the results of all items were analyzed using ❚Figure 3❚ Raw WBC count data and calculation of the 95th and 99th percentile coefficient of variation (CV) values determined using patient samples and data obtained over 3 months.
❚Figure 4❚ Acceptable range of WBC counts determined using the 95th and 99th percentile of CV cutoff values determined during the first 3 months and evaluation of the rejection rates determined during the latter 3 months using patient sample data and each predefined acceptable range. CV, coefficient of variation.
an identical method. Another 60 patient samples were obtained over 60 working days (single sample per working day) and analyzed with seven automated hematology analyzers. Using the predefined 95th and 99th percentile CV cutoff, the acceptable difference of means applicable to each day was calculated by multiplying the daily mean value by the CV cutoff value. The acceptable range of each item applicable to each day was estimated as the daily mean ± acceptable difference. The acceptance or rejection of data measured from each instrument was determined using the acceptable range with the 95th and 99th percentile CV cutoff values. For validation, the rejection rates representing the proportion of rejected days (ie, ≥1 rejected instruments per day) for all evaluated days were calculated.
To confirm the predefined 95th and 99th percentile CV cutoff values as a variable that represents the extent of biological variance in each item, we applied the ratio of maximum allowable error (MAE) to CV (MAE/CV ratio), which was explained in a previously published study, 10 to this study. Given that MAE reflects the endogenous biological variance of the item and CV indicates the overall variance (%) in each laboratory, the MAE/CV ratio can be used as a marker of acceptable variance for each laboratory item for comparison with the biological variance of the item itself. In the present study, applied MAE values for WBCs (15%), hemoglobin (7%), platelets (25%), hematocrit (6%), and five differential counts (3 SD) were derived from the Clinical Laboratory Improvement Amendments. 11 The MAE value for reticulocytes (3 SD) was derived from the Wisconsin State Laboratory of Hygiene. 12 For MCV, no new data were available, and therefore, the same MAE value (3 SD) was also applied to MCV. For WBCs, hemoglobin, platelets, and hematocrit, for which the exact MAE values were provided, MAE/CV ratios based on both the 95th and 99th percentile CV cutoff values were calculated separately. For all items, rejection rates were also estimated separately when the 95th and 99th percentile CV cutoff values were applied. The results are summarized in ❚Table 3❚.
Determination of CV Cutoff Values for the QC Materials and Validation of the Acceptable Ranges
Using the same strategy used to assess the patient samples, the 95th and 99th percentile CV cutoff values for three levels of QC materials of each item were calculated, and acceptable ranges were estimated. In this analysis, three representative instruments were used to evaluate the QC materials. To determine the acceptable ranges, we used results obtained using the same lot of QC materials during the prior 2 months. Subsequently, the MAE/CV ratios were determined using both MAE values and the predefined 95th and 99th percentile CV cutoff values. Using these data, rejection rates were estimated using results obtained during the latter 2 months as a validation process. The MAE/CV ratios and rejection rates of all items calculated are summarized in ❚Table 4❚.
Comparison of Acceptable Ranges for the QC Materials and the 99th Percentile CV Cutoff Values
To select the most appropriate calculation method, we compared acceptable ranges for three levels of the QC materials of all items calculated using the current method (mean ± 3 SD) used at our institution with acceptable ranges calculated using the 99th percentile CV cutoff values. MCV was © American Society for Clinical Pathology excluded from this analysis because the QC material for MCV is commercially unavailable. For this comparison, results obtained during the latter 2 months were used, and three representative instruments were included in the analysis. As an example, a comparison of acceptable ranges for the low QC level determined using the XE-2107 is shown in ❚Figure 5❚.
Comparison of the Reference Instrument and Six Other Instruments Using Patient Samples
Using predefined MAE data and 3 SD values determined in the present study, we compared the patient sample results obtained over 6 months using the reference instrument (XE-2108) with those from six other instruments. MAE data for each item were used as allowable total error (ATE) values in the two-instrument comparisons. Using EP evaluator release 8 software (Data Innovations North America, South Burlington, VT), we performed Deming regression and Bland-Altman analyses. Correlation equations were provided by the Deming regression analysis. Both the average error index and proportion of acceptable samples were calculated from the Bland-Altman analysis. The error index was defined as the difference between the results of the two instruments (comparative -reference) divided by ATE, and the decision criterion for acceptable samples was defined as samples with ❚Figure 5❚ Schematic boxplot comparing the acceptable ranges for low-level quality control materials determined using currently used criteria for each instrument (XE-2107) established at the authors' institution and the calculated acceptable ranges determined using the 99th percentile of CV cutoff values measured in interinstrument comparisons. CV, coefficient of variation; LL, lower limit; UL, upper limit.
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© American Society for Clinical Pathology an error index less than 1. If one comparison demonstrated a proportion of acceptable samples 95.0% or more, the comparison was considered passed, and comparisons with an acceptable sample less than 95.0% were considered failed. For failed cases in which the 3 SD value was applied as ATE values for two-instrument comparisons, different ATE values such as 4 SD, 4.5 SD, 5 SD, and 5.5 SD were subsequently applied. Acceptability was reevaluated to identify the most appropriate ATE values after considering both accuracy and effectiveness. These results are summarized in ❚Table 5❚.
Results
Acceptable Ranges Using 95th and 99th Percentile CV Cutoff Values for Patient Samples
As shown in Table 3 , the CV cutoff values calculated for the leukocyte differential counts and reticulocytes were significantly higher than those measured in other items, reflecting the high extent of variation. The calculated MAE/ CV ratios of the 95th and 99th percentile CV cutoff values were over 1.0 for WBCs, hemoglobin, platelets, and hematocrit, indicating that the CV cutoff values, which indicates technical variance in the laboratory, were within the acceptable width of biological variance in each item. These results may suggest that the 99th percentile CV cutoff values provide a broader range of acceptable ranges than the 95th percentile CV cutoff values and are sufficient for determining the acceptable range.
The rejection rates for hemoglobin, platelets, hematocrit, and MCV were high (≥10.0%) when the 95th percentile CV cutoff values were applied. The rejection rates were significantly reduced when the 99th percentile CV cutoff values were applied but were also relatively high (≥5.0%) compared with other items. Small CV values probably resulted in the high rejection rates due to the high precision of the instrument used to measure these three items.
Acceptable Ranges for QC Materials Based on the 95th and 99th Percentile CV Cutoff Values
As shown in Table 4 , all MAE/CV ratios determined using 95th and 99th percentile CV cutoff values were over 1.0 for The ATE data applied to each item (except MCV) were determined using Clinical Laboratory Improvement Amendments criteria. 11 d The ATE data applied to reticulocytes were determined using Wisconsin State Laboratory of Hygiene criteria. 12 three levels of QC materials, which is consistent with the results of the patient samples. For low-level QC materials, the rejection rates of the three differential counts (lymphocytes, monocytes, and eosinophils) and hematocrit were significantly higher than the other items when the 95th percentile CV cutoff values were applied, but the rejection rates were markedly reduced when the 99th percentile CV cutoff values were used. For normal-level QC materials, similar results were identified for basophils (%) and hematocrit, and for high-level QC materials, both WBCs and lymphocytes (%) demonstrated similar results.
Acceptable Ranges for QC Materials Based on Currently Used Method and 99th Percentile CV Cutoff Values
As shown in Figure 5 , the acceptable ranges for lowlevel QC materials of the XE-2107 according to the currently used method were wider than those calculated from the 99th percentile CV cutoff values for all items except for hematocrit. For normal-level QC materials of the XE-2107, the acceptable ranges based on the currently used method were also wider than those calculated using the 99th percentile CV cutoff values for all items. High-level QC materials of the XE-2107 also demonstrated consistent results in all items except for WBCs (16.64 × 10 3 /mL to 18.12 × 10 3 /mL for 99th percentile CV cutoff; 16.65 × 10 3 /mL to 18.12 × 10 3 /mL for currently used method). The results for the XE-2108 and XE-2105 were similar to those of the XE-2107 (data not shown). All these results indicate that the application of the 99th percentile CV cutoff values guarantees more precise inspection and provides a stricter acceptable range than in-house or manufacturervalidated acceptable methods when the QC materials are used for interinstrument comparisons.
Two-Instrument Comparisons of the Reference (XE-2108) and Six Other Instruments Using Patient Samples
As shown in Table 5 , Bland-Altman analysis showed that 23 (34.8%) comparisons failed, and the failed items consisted of leukocyte differential counts, reticulocytes, and MCV. Subsequent analysis performed to identify suitable ATE values for the 23 failed comparisons demonstrated that 20 (87.0%) comparisons passed when 4 SD was applied as an ATE value instead of 3 SD. The remaining three comparisons that also failed when using 4 SD as an ATE value were analysis of lymphocytes (%), monocytes (%), and eosinophils (%) using the XE-2105. Both lymphocytes (%) and monocytes (%) were considered passed when 5.5 SD was applied as an ATE value, and eosinophils (%) were also determined to be passed when 4.5 SD was used as an ATE value. These results indicate that the application of higher ATE values can be considered when comparing differential counts, reticulocytes, and MCV to reduce the frequency of unnecessarily followed corrective action such as recalibration, and 4 SD can be an effective ATE value in most cases.
Discussion
The currently used interinstrument comparison method applicable to CBC items requires a periodic regression analysis that uses at least more than 40 patient samples. [4] [5] [6] [7] When the laboratory uses this strategy, real-time daily interinstrument comparisons are not possible, and the consistency of multiple instruments cannot be confirmed. In addition, significant workload for the laboratory workers is inevitable. The establishment of an interinstrument comparison method that can be performed daily and is suitable for both patient specimens and QC materials is expected to significantly improve reporting quality and laboratory workflow. In the present study, we established an interinstrument comparison method using 99th percentile CV cutoff values of the daily mean calculated from results of multiple instruments to determine the acceptable range for each result and validated the practical relevance of this method using both patient samples and QC materials.
Here, analysis using patient samples demonstrated that the calculated MAE/CV ratios based on the 95th and 99th percentile CV cutoff values for WBCs, hemoglobin, platelets, and hematocrit were similar, ranging from 3.8 to 7.0 and from 3.6 to 5.6, respectively. These results may reflect the clinical usefulness of the 99th percentile CV cutoff values in the determination of daily acceptable ranges for interinstrument comparisons. Although the rejection rates for hemoglobin, platelets, hematocrit, and MCV were significantly reduced when the 99th percentile CV cutoff values were applied instead of 95th percentile CV cutoff values, the rejection rates were still relatively high, and we speculate that the extremely small CV values in these variables, which indicate the high precision of the instrument and subsequently narrow acceptable range, could result in the high rejection rates of these items. These results may provide the rationale that the ATE values used to determine the acceptance of two-instrument comparisons may be adjusted to less stringent criteria (eg, 4 SD values) to reduce the frequency of unnecessarily followed corrective action such as recalibration of a specific instrument if high rejection rates are consistently maintained in a specific item. Analyses with three levels of QC materials also demonstrated the practical relevance of the 99th percentile of CV cutoff values for interinstrument comparisons, because similar results, such as the significant reduction of rejection rates, were also found for some items. These results underscore the usefulness of the 99th percentile of the CV cutoff values for real-time daily interinstrument comparisons, which is applicable to both patient samples and QC materials.
Our present study also shows that the acceptable ranges calculated using the 99th percentile of the CV cutoff values provide stricter acceptable ranges than currently used DOI: 10.1309/AJCPP0F9QXYOUJOG © American Society for Clinical Pathology in-house methods for most items when three levels of QC materials are used for interinstrument comparisons. These results indicate that the application of 99th percentile CV cutoff value-derived acceptable ranges enables the more precise inspection of QC results than currently used methods, which also justifies the application of 99th percentile CV cutoff values.
In this study, two-instrument comparisons using patient samples yielded relatively high failure rates of 34.8% when 3 SD was applied as an ATE value, and the failed items included five differential counts, reticulocytes, and MCV. These results suggest that for some items, more broadly modified ATE values should be applied to reduce the number of failed comparisons. Subsequent analysis confirmed that applying 4 SD as an ATE value can reduce 87.0% of failed comparisons. Accordingly, we suggest that higher ATE values may be required to compare differential counts, reticulocytes, and MCV to reduce the frequency of unnecessarily followed recalibration, and 4 SD can be an effective ATE value in these cases. Our present study demonstrated consistently failed results in multiple instruments in two-instrument comparisons of leukocyte differential counts, especially for segmented neutrophils, eosinophils, and basophils when 3 SD was applied as an ATE value, and the cause of these results is not clear. Given that the applied ATE value (3 SD) in the leukocyte differential counts is designed to be calculated from the measured results, not the exactly predefined value (eg, 15% for WBCs), we cannot certify that the increase of failed results in these items is attributed to endogenous high biological variability or inaccurate analysis of instruments in these items. However, the consistency of failed results in all six instruments, which was identified in our present study, may suggest the cause to be endogenous high biological variability rather than analytic inaccuracy of specific instruments. More precise study focused on this issue is needed to confirm the exact cause of our present results.
On the basis of these results, we can suggest a new guideline applicable to the real-time interinstrument comparisons used in the laboratory that operates multiple instuments: the 99th percentile CV cutoff value-derived daily acceptable ranges can be used as a real-time interinstrument comparison method, and as a validation, both rejection rates and the MAE/CV ratio should be monitored. The rejection rates are monitored with two purposes: to find out the specific instrument with consistently failed results (beyond acceptable ranges) and to discover the item with consistently high rejection rates, which may be a candidate item in which less stringent ATE values (eg, 4 SD values) can be applied when two-instrument comparisons are performed to reduce unnecessarily followed corrective action such as recalibration. Corrective actions such as recalibration should be required only if the CV cutoff value is greater than the MAE value, which indicates the significant imprecision of the instrument beyond the biological variance of the item.
Since this approach was validated in a laboratory that operates seven instruments, the appropriateness of this approach needs to be evaluated for a laboratory with a small number of instruments. The 99th percentile CV cutoff values can be calculated in this situation, but the limited number of measured results may theoretically result in the increase in CV cutoff values, and calculated acceptable ranges may be less stringent, which may interfere with the rigorous evaluation. Therefore, we would suggest that the application of this approach is preferred in a laboratory operating a large number of instuments rather than a small number. More specified study focused on the clinical relevance of this approach in a relatively small-sized laboratory is required in the future.
The present study is limited in terms of statistical power. Since the 99th percentile CV cutoff values were derived from data obtained from 60 patient samples and 47 QC materials of three levels, the insufficient number of samples may limit the accurate estimation of the 99th percentile CV cutoff values. In addition, validation of the predefined 99th percentile CV cutoff values was insufficient due to the lack of adequate validated samples. Therefore, the estimated rejection rates demonstrate less statistical power and need to be readdressed by using more samples. A larger study that includes more samples is needed to confirm the clinical relevance and application of the 99th percentile CV cutoff values and determine more accurate acceptable ranges for the interinstrument comparisons.
In conclusion, we suggest that 99th percentile CV cutoff value-derived daily acceptable ranges be used as a real-time interinstrument comparison method for assessing both patient samples and QC materials. When QC materials are used, the acceptable ranges calculated from the 99th percentile CV cutoff values should be used rather than the in-house or manufacturer-derived acceptable range. For some items such as differential counts, reticulocytes, and MCV, applying modified ATE values such as 4 SD can significantly reduce the frequency of unnecessarily followed recalibrations in the application of two-instrument comparisons.
